TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21256805
Drug: Pimavanserin (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimavanserin (1, 2.5, 5, or 20 mg)
Study: 9753527
Drug: Salmeterol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol (100 mg daily)
Study: 9753527
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (1 mg daily)
Study: 3337274
Drug: Clonidine skin
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine skin patch for 48 hours prior to study
Study: 3337274
Drug: Placebo skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo skin patch for 48 hours prior to study
Study: 20964660
Drug: Calcipotriene/betamethasone dipropionate
Normalized name: calcipotriene/betamethasone dipropionate 0.005 %-0.064 % TOPICAL FOAM (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriene/betamethasone dipropionate two-compound scalp formulation (n=135)
Study: 20964660
Drug: Calcipotriene/betamethasone dipropionate
Normalized name: calcipotriene/betamethasone dipropionate 0.005 %-0.064 % TOPICAL FOAM (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriene/betamethasone dipropionate two-compound scalp formulation
Study: 16331635
Drug: 4 courses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 courses of dose-escalated CHOP plus etoposide (megaCHOEP)
Study: 16331635
Drug: 6 courses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 courses of dose-escalated CHOP plus etoposide (megaCHOEP)
Study: 14616412
Drug: Voriconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voriconazole (200 mg twice daily) + Phenytoin (300 mg once daily)
Study: 14616412
Drug: Voriconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voriconazole (400 mg twice daily) + Phenytoin (300 mg once daily)
Study: 14616412
Drug: Phenytoin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenytoin (300 mg once daily) + Voriconazole (400 mg twice daily)
Study: 11591255
Drug: Non-professional hCG
Normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-professional hCG administration
Study: 3251162
Drug: Saline (NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (NaCl 150 mmol/1-50 ml/h)
Study: 20953418
Drug: No treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment, sham procedure, or usual biomedical care
Study: 11203780
Drug: Additional enamel
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional enamel etching with 37% phosphoric acid gel (K-etchant)
Study: 15168719
Drug: Three-drug combinations
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-drug combinations of stavudine (d4T), lamivudine (3TC), and indinavir
Study: 15168719
Drug: Three-drug combinations
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-drug combinations of d4T, didanosine (ddI), and indinavir
Study: 15168719
Drug: Three-drug combinations
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-drug combinations of zidovudine (ZDV), 3TC, and indinavir
Study: 15168719
Drug: Two-drug combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-drug combinations of d4T and 3TC
Study: 15168719
Drug: Two-drug combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-drug combinations of d4T and ddI
Study: 15168719
Drug: Two-drug combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-drug combinations of ZDV and 3TC
Study: 15168719
Drug: Two-drug combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-drug combinations of ZDV and ddI
Study: 7808748
Drug: Loratadine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine (10 mg daily for 3 weeks)
Study: 7808748
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 tablet daily for 8-10 days)
Study: 787013
Drug: Non-surgical regime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical regime (scaling and oral hygiene instruction)
Study: 25956718
Drug: Restrictive RBC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive RBC transfusion policy (transfusion when haemoglobin concentration fell below 80 g/L)
Study: 25956718
Drug: Liberal RBC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberal RBC transfusion policy (transfusion when haemoglobin concentration fell below 100 g/L)
Study: 23364005
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g n-3 PUFA-containing lipid (70% EPA plus 10% DHA) daily for 3 months
Study: 20224148
Drug: Prebiotic-added formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prebiotic-added formula (0.8 g/dl of a mixture from scGOS and lcFOS, ratio 9:1)
Study: 20224148
Drug: Probiotic-added formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic-added formula (L. reuteri at dose of 1x10(8) CFU per day)
Study: 17263930
Drug: Treatment algorithm
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment algorithm for hypertension
Study: 11678953
Drug: Substance P
Normalized name: Substance P
DrugBank: Substance P (DB19198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substance P (10 and 80 nmol/mL) applied to nasal mucosa
Study: 8782976
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with one antiepileptic drug
Study: 8782976
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with another antiepileptic drug
Study: 20636243
Drug: 25 microg
Normalized name: Digoxin 125 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 microg intravaginal misoprostol every 6 hours for a maximum of four doses
Study: 20636243
Drug: 14-F Foley
Normalized name: F
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-F Foley catheter plus intravenous oxytocin initiated after balloon extrusion or after 24 hours
Study: 18413703
Drug: Fluoxetine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine alone (10‐40 mg/day)
Study: 18413703
Drug: CBT combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT combined with fluoxetine (10‐40 mg/day)
Study: 18413703
Drug: Placebo (equivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (equivalent to 10‐40 mg/day)
Study: 11844743
Drug: Combined antiresorptive
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined antiresorptive therapies
Study: 1445474
Drug: Drug groups
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug groups
Study: 31658058
Drug: Hydromethylthionine at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromethylthionine at 8 mg/day (control dose)
Study: 31658058
Drug: Hydromethylthionine at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromethylthionine at higher doses (4-21 ng/ml)
Study: 31658058
Drug: Hydromethylthionine at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromethylthionine at 16 mg/day (predicted optimal dose)
Study: 25750519
Drug: Test drug
Normalized name: URINE TEST DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drug (tramadol formulation)
Study: 21675059
Drug: Daily sedation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily sedation interruption
Study: 19319008
Drug: Home-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based therapy (pencil push-ups)
Study: 18001519
Drug: Rivastigmine transdermal
Normalized name: Rivastigmine Transdermal System
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine transdermal patch (4.6 mg/24 hour, 5 cm²)
Study: 18001519
Drug: Rivastigmine transdermal
Normalized name: Rivastigmine Transdermal System
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine transdermal patch (9.5 mg/24 hour, 10 cm²)
Study: 18001519
Drug: Rivastigmine capsules
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine capsules (3 mg BID, 6 mg/day)
Study: 18001519
Drug: Rivastigmine capsules
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine capsules (6 mg BID, 12 mg/day)
Study: 8419555
Drug: Bromocriptine, 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine, 1.25 mg, three times per day for two weeks
Study: 25020155
Drug: Control (similar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (similar levels of non-medication-related contact)
Study: 23635728
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (500 mg, three times daily)
Study: 21068481
Drug: Epoetin beta
Normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Epoetin beta 10,000 IU thrice weekly (TW)
Study: 21068481
Drug: Epoetin beta
Normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Epoetin beta 30,000 IU once weekly (OW)
Study: 21068481
Drug: Epoetin beta
Normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Epoetin beta therapy (both schedules)
Study: 10933122
Drug: Routine assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine assessment and treatment as usual (ATU)
Study: 1573032
Drug: Tranylcypromine (TCP)
DrugBank: Tranylcypromine (DB00752)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranylcypromine (TCP) 30 mg (target dose), actual mean dose 18.5 mg
Study: 1573032
Drug: Amitriptyline (AMI)
DrugBank: Amitriptyline (DB00321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amitriptyline (AMI) 150 mg (target dose), actual mean dose 114.3 mg
Study: 1573032
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of TCP and AMI (target doses: TCP 30 mg, AMI 150 mg; actual mean doses: TCP 19.7 mg, AMI 108.7 mg)
Study: 3523369
Drug: Topically administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topically administered alpha‐adrenoceptor agonist (phenylpropanolamine)
Study: 23523540
Drug: High-frequency vibration
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-frequency vibration training (32 Hz, 1mm, 4 g)
Study: 23523540
Drug: Low-frequency vibration
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-frequency vibration training (18 Hz, 3 mm, 4 g)
Study: 21977860
Drug: Zishengukang Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zishengukang Pill with Western medicine
Study: 9310720
Drug: Hydrocortisone acetate
Normalized name: Hydrocortisone Acetate
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone acetate 0.5% (Cortaid Cream)
Study: 9310720
Drug: Clobetasone butyrate
Normalized name: clobetasone butyrate
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Clobetasone butyrate 0.05% (Eumovate Cream)
Study: 9310720
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate 0.05% (Clobesol Cream)
Study: 2430606
Drug: Vecuronium 0.12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.12 mg kg‐1
Study: 27020669
Drug: High-salt diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-salt diet plus potassium supplement for 7 days
Study: 24998242
Drug: Cognitive working
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive working memory training (computer-based program, 25 daily sessions over 5 to 6 weeks)
Study: 21835953
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (ASA) 100 mg/d (n = 176)
Study: 21835953
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH) enoxaparin 40 mg/d (n = 166)
Study: 19832854
Drug: Teriparatide (TPTD)
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Teriparatide (TPTD) - human recombinant PTH 1-34, 20 microg daily injections for 18 months
Study: 15952104
Drug: PEG‐IFN‐alfa 2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFN‐alfa 2b 1.5 or 3.0 microg/kg/wk (split-dose)
Study: 15952104
Drug: IFN‐alfa 2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN‐alfa 2b 3 mIU 3 times weekly
Study: 8739019
Drug: S-1452 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1452 (10 mg, 25 mg, 50 mg)
Study: 1763923
Drug: Nicardipine LA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine LA 50 mg administered twice daily
Study: 6980756
Drug: Allogeneic tumor
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic tumor vaccine
Study: 6980756
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not receiving tumor vaccine)
Study: 30334124
Drug: Laser photobiomodulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser photobiomodulation therapy (lPBMt) with an exercise program for 8 weeks
Study: 30334124
Drug: Ultrasound therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound therapy (UST) with an exercise program for 8 weeks
Study: 19491386
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (ascorbic acid, 500 mg every day)
Study: 19491386
Drug: Beta-carotene (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (50 mg every other day)
Study: 16937979
Drug: 40 g.d(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g.d(‐1) of whey protein + 8 g.d(‐1) of casein (WC)
Study: 16937979
Drug: 40 g.d(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g.d(‐1) of whey protein + 3 g.d(‐1) branched-chain amino acids + 5 g.d(‐1) L-glutamine (WBG)
Study: 16937979
Drug: 48 g
Normalized name: GLYCERIN 3 g in 48 g CUTANEOUS OINTMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 48 g per day (g.d(‐1)) carbohydrate placebo (P)
Study: 14962152
Drug: Doxycycline 200
Normalized name: doxycycline 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 200 mg and rifampin 300 mg daily for 3 months
Study: 11738746
Drug: 23‐valent pneumococcal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23‐valent pneumococcal polysaccharide vaccine (PSV)
Study: 11738746
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (conjugate Haemophilus influenzae type b (HbOC) vaccine)
Study: 9158644
Drug: Indobufen (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indobufen (100 or 200 mg BID)
Study: 9158644
Drug: Warfarin (to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (to obtain an international normalized ratio of 2.0 to 3.5)
Study: 3067479
Drug: Pentoxifyllin 1200
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifyllin 1200 mg daily for 3 months
Study: 23763082
Drug: Luliconazole cream
Normalized name: Luliconazole Cream
DrugBank: Luliconazole (DB08933)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Luliconazole cream 1% for 2 weeks
Study: 23763082
Drug: Luliconazole cream
Normalized name: Luliconazole Cream
DrugBank: Luliconazole (DB08933)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Luliconazole cream 1% for 4 weeks
Study: 21398574
Drug: ProDisc-L total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: ProDisc-L total disc replacement
Study: 16091238
Drug: Effective treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effective treatment of curable STIs
Study: 11601117
Drug: Losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50 to 100 mg, once daily)
Study: 9606227
Drug: Immediate bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate bolus strategy (3 mL intratracheal bolus of calf lung surfactant extract - Infasurf administered before positive pressure ventilation)
Study: 9606227
Drug: Postventilatory aliquot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postventilatory aliquot strategy (3 mL of surfactant administered in 4 divided aliquots of 0.75 mL each at 10 minutes after birth)
Study: 7740450
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) 150 U/kg s.c.
Study: 7740450
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose LMWH 35 U/kg s.c.
Study: 7740450
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose LMWH 75 U/kg s.c.
Study: 2557322
Drug: NaHCO3 (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaHCO3 (0.3 g NaHCO3/kg body wt)
Study: 2557322
Drug: NaHCO3 (0.12
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaHCO3 (0.12 g NaHCO3/kg body wt initially, with 0.18 g/kg body wt distributed in equal doses before each 5‐min exercise bout)
Study: 1222886
Drug: C-3 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-3 (2 g statim plus 6 g by continuous drip infusion over 24 hrs for 5 days)
Study: 28485320
Drug: Aerosolized Amikacin
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Aerosolized Amikacin (400 mg, q8h) for 7 days
Study: 28485320
Drug: Placebo (saline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline, 4 ml, q8h) for 7 days
Study: 22118109
Drug: Ceftiofur hydrochloride
Normalized name: Ceftiofur Hydrochloride
DrugBank: Ceftiofur (DB11485)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftiofur hydrochloride intramammary infusion at 24-hour intervals for 5 days
Study: 22118109
Drug: Ceftiofur hydrochloride
Normalized name: Ceftiofur Hydrochloride
DrugBank: Ceftiofur (DB11485)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftiofur hydrochloride intramammary infusion
Study: 17110799
Drug: Carvedilol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (25 or 50 mg)
Study: 8317790
Drug: Aerosolized recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized recombinant human deoxyribonuclease (rhDNase) 0.6 mg twice daily
Study: 8317790
Drug: Aerosolized recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized recombinant human deoxyribonuclease (rhDNase) 2.5 mg twice daily
Study: 8317790
Drug: Aerosolized recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized recombinant human deoxyribonuclease (rhDNase) 10.0 mg twice daily
Study: 22739373
Drug: Salmon consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmon consumption (2 portions of farmed salmon per week providing 3.45 g long‐chain (LC) (n‐3) PUFA/wk)
Study: 18318696
Drug: Pepsi Cola
Normalized name: cola extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pepsi Cola added to 0.75 mg x kg(‐1) midazolam
Study: 18318696
Drug: 10% sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% sodium citrate added to 0.75 mg x kg(‐1) midazolam
Study: 18318696
Drug: Pomegranate juice
Normalized name: pomegranate juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate juice added to 0.75 mg x kg(‐1) midazolam
Study: 18318696
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice added to 0.75 mg x kg(‐1) midazolam
Study: 18318696
Drug: 0.75 mg
Normalized name: propinox 0.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg x kg(‐1) midazolam without any additive
Study: 9527730
Drug: Propofol sedation
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol sedation (5 mg kg(‐1) h(‐1) initially, titrated to 2.4+/‐0.7 mg kg(‐1) h(‐1))
Study: 7629525
Drug: Aspirin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (30 or 283 mg)
Study: 2799022
Drug: Tiapride (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiapride (7.5 mg/kg)
Study: 62946
Drug: Rifampicin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin plus isoniazid for nine months, supplemented by ethambutol (25 mg/kg for the first two months)
Study: 30796855
Drug: Exogenous lactase
Normalized name: Lactase
DrugBank: Tilactase (DB13761)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exogenous lactase preparation
Study: 22145355
Drug: 2% acid‐soluble
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% acid‐soluble chitosan solution (200‐250 kDa molecular weight)
Study: 19628651
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of acylated ghrelin (AG) 100 microg and unacylated ghrelin (UAG) 100 microg (Comb)
Study: 27272073
Drug: Topical agent
Normalized name: topical agent combination no.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical agent designed to reduce P. acnes biofilm
Study: 10822123
Drug: Estrogen replacement
Normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen replacement therapy (0.625 mg/day oral conjugated estrogen)
Study: 10822123
Drug: Estrogen replacement
Normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen replacement therapy with continuous low-dose progestin (2.5 mg oral medroxyprogesterone acetate/day)
Study: 6405431
Drug: Alcoholic beverage
Normalized name: Alcoholic beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcoholic beverage (0.50 g/kg body weight)
Study: 20236248
Drug: ADX10059 125
Normalized name: ADX10059
DrugBank: ADX10059 (DB05070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADX10059 125 mg b.i.d.
Study: 20236248
Drug: ADX10059 250
Normalized name: ADX10059
DrugBank: ADX10059 (DB05070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADX10059 250 mg b.i.d.
Study: 17261559
Drug: Eccentric training
Normalized name: SYRINGE 60ML ECCENTRIC TIP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eccentric training (various protocols including drop squats, slow eccentric movement, squatting on decline board or level ground, etc.) for 12 weeks, twice daily.
Study: 15855570
Drug: INH (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: INH (6 mg)
Study: 11997197
Drug: Avinza 30
Normalized name: Avinza 30mg Extended-Release Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avinza 30 mg once daily
Study: 11997197
Drug: MS Contin
Normalized name: MS Contin
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MS Contin 15 mg twice daily
Study: 30107283
Drug: MEDI3902 (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI3902 (250 mg)